GlassScriptPhysician profile
Harry L Uy
NPI 1962541466
$8,737.36
in general payments reported to CMS, 2019-2025
42 companies · $4,306 in 2025
The $4,306 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $279 · 2021: $66.74 · 2022: $307 · 2023: $1,015 · 2024: $2,246 · 2025: $4,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,345 · Consulting Fee: $175 · Education: $47.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,345.42 |
| Consulting Fee | $175.00 |
| Education | $47.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,142.00 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,109.23 | 2019-2025 | Tepezza, Prolia, Evenity |
| Dexcom, INC. | $652.71 | 2023-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Radius Health, INC. | $623.52 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $456.86 | 2024-2025 | Korlym |
| Abbott Laboratories | $442.67 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $394.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $381.41 | 2022-2025 | Minimed 780g |
| Cequr Corporation | $364.26 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $329.73 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $325.16 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.78 | 2023-2025 | Jardiance, Synjardy |
| Recordati_rare_diseases_inc. | $202.20 | 2024-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $175.15 | 2023-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $169.65 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $150.08 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $149.09 | 2023-2025 | |
| Intuity Medical INC | $148.66 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Insulet Corporation | $139.38 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $131.27 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $125.40 | 2024-2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $113.66 | 2024-2025 | Unithroid |
| Kyowa Kirin, INC. | $93.79 | 2024-2025 | Crysvita |
| Acella Pharmaceuticals, LLC | $71.90 | 2024-2025 | NP Thyroid 60 |
| Ascendis Pharma Endocrinology INC | $67.31 | 2025 | Yorvipath |
| Tolmar, INC. | $62.93 | 2023-2025 | Jatenzo |
| Soleno Therapeutics, INC. | $58.19 | 2025 | Vykat Xr |
| Alexion Pharmaceuticals, INC. | $49.88 | 2024-2025 | Strensiq |
| Chiesi USA, INC. | $48.81 | 2024-2025 | Mycapssa |
| Neurocrine Biosciences, INC. | $34.52 | 2025 | |
| Sequel Med Tech, LLC | $25.60 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $24.80 | 2024 | |
| Pfizer INC. | $24.25 | 2025 | |
| Almatica Pharma LLC | $23.12 | 2025 | Teriparatide |
| Sandoz INC. | $22.37 | 2025 | Jubbonti |
| Acerus Pharmaceuticals Corporation | $21.71 | 2020 | |
| Antares Pharma, INC. | $20.28 | 2024 | Xyosted |
| Amphastar Pharmaceuticals, INC. | $16.26 | 2024 | |
| Ibsa Pharma INC. | $16.02 | 2024 | Licart, Tirosint |
| Rgh Enterprises LLC | $16.00 | 2025 | |
| Medtronic Minimed, INC. | $13.62 | 2020 | |
| Madrigal Pharmaceuticals | $13.51 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Uy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.